Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients.
Very undervalued with flawless balance sheet.
Share Price & News
How has Vanda Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: VNDA's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: VNDA underperformed the US Biotechs industry which returned 6.5% over the past year.
Return vs Market: VNDA underperformed the US Market which returned 10.5% over the past year.
Price Volatility Vs. Market
How volatile is Vanda Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StWe Wouldn't Rely On Vanda Pharmaceuticals's (NASDAQ:VNDA) Statutory Earnings As A Guide
1 month ago | Simply Wall StDon't Ignore The Fact That This Insider Just Sold Some Shares In Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)
3 months ago | Simply Wall StShould We Be Delighted With Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) ROE Of 30%?
Is Vanda Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: VNDA ($11.47) is trading below our estimate of fair value ($64.5)
Significantly Below Fair Value: VNDA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: VNDA is good value based on its PE Ratio (5x) compared to the Biotechs industry average (18.4x).
PE vs Market: VNDA is good value based on its PE Ratio (5x) compared to the US market (17.2x).
Price to Earnings Growth Ratio
PEG Ratio: VNDA is good value based on its PEG Ratio (0.4x)
Price to Book Ratio
PB vs Industry: VNDA is good value based on its PB Ratio (1.5x) compared to the US Biotechs industry average (3x).
How is Vanda Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VNDA's forecast earnings growth (13.3% per year) is above the savings rate (1.7%).
Earnings vs Market: VNDA's earnings (13.3% per year) are forecast to grow faster than the US market (13.2% per year).
High Growth Earnings: VNDA's earnings are forecast to grow, but not significantly.
Revenue vs Market: VNDA's revenue (14.4% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: VNDA's revenue (14.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if VNDA's Return on Equity is forecast to be high in 3 years time
How has Vanda Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VNDA has a high level of non-cash earnings.
Growing Profit Margin: VNDA's current net profit margins (55.5%) are higher than last year (7.1%).
Past Earnings Growth Analysis
Earnings Trend: VNDA has become profitable over the past 5 years, growing earnings by 30.6% per year.
Accelerating Growth: VNDA's earnings growth over the past year (835.4%) exceeds its 5-year average (30.6% per year).
Earnings vs Industry: VNDA earnings growth over the past year (835.4%) exceeded the Biotechs industry 66.2%.
Return on Equity
High ROE: VNDA's Return on Equity (30.4%) is considered high.
Return on Assets
Return on Capital Employed
How is Vanda Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: VNDA's short term assets ($280.0M) exceed its short term liabilities ($60.0M).
Long Term Liabilities: VNDA's short term assets ($280.0M) exceed its long term liabilities ($13.5M).
Debt to Equity History and Analysis
Debt Level: VNDA is debt free.
Reducing Debt: VNDA has not had any debt for past 5 years.
Inventory Level: VNDA has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if VNDA's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VNDA is profitable, therefore cash runway is not a concern.
Forecast Cash Runway: VNDA is profitable, therefore cash runway is not a concern.
What is Vanda Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate VNDA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate VNDA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if VNDA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if VNDA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of VNDA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mihael Polymeropoulos (59yo)
Dr. Mihael H. Polymeropoulos, M.D. founded Vanda Pharmaceuticals, Inc. in 2003 and has been its Chief Executive Officer, President and Director since May, 2003. Dr. Polymeropoulos has also been the Chief F ...
CEO Compensation Analysis
Compensation vs Market: Mihael's total compensation ($USD4.28M) is above average for companies of similar size in the US market ($USD2.57M).
Compensation vs Earnings: Mihael's compensation has been consistent with company performance over the past year.
|Executive VP||9.2yrs||US$2.24m||0.21% $1.3m|
|Senior VP||1.5yrs||US$3.43m||0.0092% $57.9k|
|Senior Vice President of Business Development||2.9yrs||US$2.00m||0.28% $1.7m|
|Senior VP & Chief Commercial Officer||4.4yrs||US$2.28m||0.15% $962.0k|
|Chief Corporate Affairs & Communications Officer||0.5yrs||no data||no data|
|Chief Marketing Officer||0.5yrs||no data||no data|
|Chief People Officer||0.5yrs||no data||no data|
|Head of Corporate Affairs||0yrs||no data||no data|
Experienced Management: VNDA's management team is considered experienced (2.2 years average tenure).
|Independent Director||14.2yrs||US$264.35k||0.058% $361.7k|
|Independent Chairman of the Board||5.9yrs||US$281.85k||0.047% $293.9k|
|Director||0.3yrs||no data||no data|
|Independent Director||0yrs||no data||0.00037% $2.3k|
|Director||0.8yrs||no data||no data|
Experienced Board: VNDA's board of directors are considered experienced (5.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: VNDA insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8%.
Vanda Pharmaceuticals Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Vanda Pharmaceuticals Inc.
- Ticker: VNDA
- Exchange: NasdaqGM
- Founded: 2002
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$626.977m
- Shares outstanding: 53.34m
- Website: https://www.vandapharma.com
Number of Employees
- Vanda Pharmaceuticals Inc.
- 2200 Pennsylvania Avenue NW
- Suite 300E
- District Of Columbia
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|VNDA||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Apr 2006|
|VM4||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Apr 2006|
|0LKB||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Apr 2006|
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company’s marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia. Its products also include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; VTR-297, a small molecule histone deacetylase inhibitor, which is in clinical development stage for the treatment of hematologic malignancies; and VQW-765, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. In addition, the company is developing cystic fibrosis transmembrane conductance regulator activators and inhibitors. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/26 00:37|
|End of Day Share Price||2020/02/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.